122 related articles for article (PubMed ID: 30321129)
21. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
Kasper AM; Ridpath AD; Gerona RR; Cox R; Galli R; Kyle PB; Parker C; Arnold JK; Chatham-Stephens K; Morrison MA; Olayinka O; Preacely N; Kieszak SM; Martin C; Schier JG; Wolkin A; Byers P; Dobbs T
Clin Toxicol (Phila); 2019 Jan; 57(1):10-18. PubMed ID: 29989463
[TBL] [Abstract][Full Text] [Related]
22. Mental illness and substance use problems in relation to homelessness onset.
Childress S; Reitzel LR; Maria DS; Kendzor DE; Moisiuc A; Businelle MS
Am J Health Behav; 2015 Jul; 39(4):549-55. PubMed ID: 26018103
[TBL] [Abstract][Full Text] [Related]
23. A Polydrug and Psychosocial Profile of Synthetic Cannabinoid Use in a New York City Community Sample, 2016-2017.
Joseph A; Lekas HM; Manseau M; Lewis C
Subst Use Misuse; 2019; 54(2):282-287. PubMed ID: 30526203
[TBL] [Abstract][Full Text] [Related]
24. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting.
Joseph AM; Manseau MW; Lalane M; Rajparia A; Lewis CF
Am J Drug Alcohol Abuse; 2017 Jan; 43(1):117-122. PubMed ID: 27797288
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency Setting.
Manseau MW; Rajparia A; Joseph A; Azarchi S; Goff D; Satodiya R; Lewis CF
Subst Use Misuse; 2017 May; 52(6):822-825. PubMed ID: 28156305
[TBL] [Abstract][Full Text] [Related]
26. Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison.
Ralphs R; Williams L; Askew R; Norton A
Int J Drug Policy; 2017 Feb; 40():57-69. PubMed ID: 27955961
[TBL] [Abstract][Full Text] [Related]
27. Kratom exposures reported to Texas poison centers.
Forrester MB
J Addict Dis; 2013; 32(4):396-400. PubMed ID: 24325774
[TBL] [Abstract][Full Text] [Related]
28. Synthetic cannabinoid use among college students.
Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
[TBL] [Abstract][Full Text] [Related]
29. NBOMe designer drug exposures reported to Texas poison centers.
Forrester MB
J Addict Dis; 2014; 33(3):196-201. PubMed ID: 25115175
[TBL] [Abstract][Full Text] [Related]
30. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
Cairns R; Brown JA; Gunja N; Buckley NA
Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
[TBL] [Abstract][Full Text] [Related]
31. Synthetic Cannabinoid Use and Descriptive Norms among Collegiate Student-Athletes.
Egan KL; Erausquin JT; Milroy JJ; Wyrick DL
J Psychoactive Drugs; 2016; 48(3):166-72. PubMed ID: 27224428
[TBL] [Abstract][Full Text] [Related]
32. Adolescent exposures to traditional and novel psychoactive drugs, reported to National Poison Data System (NPDS), 2007-2017.
Ng PC; Banerji S; Graham J; Leonard J; Wang GS
Drug Alcohol Depend; 2019 Sep; 202():1-5. PubMed ID: 31279256
[TBL] [Abstract][Full Text] [Related]
33. Homelessness and Mortality Among Persons With Tuberculosis in Texas, 2010-2017.
Agarwal S; Nguyen DT; Graviss EA
Public Health Rep; 2019; 134(6):643-650. PubMed ID: 31539480
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of acute occupational pesticide exposures reported to poison control centers in Texas, 2000-2015.
Trueblood AB; Shipp EM
Arch Environ Occup Health; 2018 Jul; 73(4):228-235. PubMed ID: 28605270
[TBL] [Abstract][Full Text] [Related]
35. Hallucinogenic mushroom misuse reported to Texas poison centers.
Forrester MB
J Addict Dis; 2020; 38(4):482-488. PubMed ID: 32627708
[TBL] [Abstract][Full Text] [Related]
36. Synthetic Cannabinoid Abuse in Adolescents: A Case Series.
Besli GE; Ikiz MA; Yildirim S; Saltik S
J Emerg Med; 2015 Nov; 49(5):644-50. PubMed ID: 26293411
[TBL] [Abstract][Full Text] [Related]
37. Novel psychoactive drug use among younger adults involved in US nightlife scenes.
Kelly BC; Wells BE; Pawson M; Leclair A; Parsons JT; Golub SA
Drug Alcohol Rev; 2013 Nov; 32(6):588-93. PubMed ID: 23795887
[TBL] [Abstract][Full Text] [Related]
38. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
39. Methamphetamine exposures reported to United States poison control centers, 2000-2019.
Chen T; Spiller HA; Badeti J; Funk AR; Zhu M; Smith GA
Clin Toxicol (Phila); 2021 Aug; 59(8):705-714. PubMed ID: 33403876
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of synthetic cannabinoids in serum samples--epidemiology and consumption patterns.
Jaenicke NJ; Pogoda W; Paulke A; Wunder C; Toennes SW
Forensic Sci Int; 2014 Sep; 242():81-87. PubMed ID: 25050839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
